Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-09

Study Completion Date

2026-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000. The severity of the disease varies depending on the type of disease and may even lead to death. This disease is caused by a genetic mutation in keratin or collagen, and its incidence is the same in all men and women of different human races. In these patients, the skin becomes extremely fragile and peels off with the slightest scratch. Many blisters are one of the most obvious symptoms of this disease. The possibility of skin cancer in people suffering from this disease is more than others.

Nowadays, the preference of cell therapy methods is to use biological products produced by cells such as extracellular vesicles and mitochondria instead of stem cells. The use of Extracellular vesicles and engineered EVs as messenger carriers can introduce a new treatment method based on cell products for skin regeneration and as an alternative to cell therapy.

Therefore, in this study, EV.FV will be applied topically to patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Computational Drug Repurposing for All EBS Cases

NCT03269474

Epidermolysis Bullosa Healthy Genetic Skin Disease +3 more

RECRUITING

Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa

NCT00904163

Epidermolysis Bullosa Dystrophica

COMPLETED

Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer

NCT00533572

Epidermolysis Bullosa Dystrophica

TERMINATED

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573

Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Junctional

RECRUITING

Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa

NCT01908088

Epidermolysis Bullosa With Mitten Hands

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mesenchymal stem cell-derived EV which included Five Factors act as cell-free nanovesicles that mediate intercellular communication by transferring functional biomolecules including mRNA, microRNA, proteins, and lipids to recipient skin cells. In dystrophic epidermolysis bullosa, these exosomes facilitate wound repair and regeneration through several mechanisms: (1) modulation of inflammation by down-regulating pro-inflammatory cytokines; (2) stimulation of fibroblast and keratinocyte proliferation and migration; (3) promotion of angiogenesis via vascular endothelial growth factor (VEGF) signaling; and (4) potential delivery of collagen VII related proteins and mRNAs that support dermal epidermal junction repair. Thus, the therapeutic benefit of exosome therapy arises from paracrine signaling and molecular cargo transfer rather than cell engraftment, providing a safer and more controlled alternative to live stem cell transplantation.

Our study focused on dystrophic EB (DEB), the most severe form, where loss of collagen VII disrupts anchoring fibrils and dermal-epidermal adhesion. This pathology makes DEB an appropriate target for regenerative therapies such as mesenchymal stem cell-derived EVs and investigates if EVs from MSCs are safe and effective for treating DEB. It will examine how well these exosomes help heal wounds and promote tissue regeneration, hoping to find a new biological treatment option for this challenging disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dystrophic Epidermolysis Bullosa Wound Heal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Qualified patients who have confirmed chronic wounds (10-50cm2) are included in the study after completing the consent form

Group Type EXPERIMENTAL

Ev.FV 1.0 x 1011 par/ml

Intervention Type BIOLOGICAL

Ev.FV 1.0 x 1011 par/ml, IV, Total of 6 doses every 2weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ev.FV 1.0 x 1011 par/ml

Ev.FV 1.0 x 1011 par/ml, IV, Total of 6 doses every 2weeks

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DEB participants determined by electron microscopy, or genetic testing. Individuals with severe DEB (eg, RDEB patients with an absence of collagen VII) and milder forms of DEB (eg, RDEB patients with reduced levels of collagen VII) will be eligible.
* People with one or more active wounds (each between 10 and 50 square centimeters on the arms, legs or trunk.)
* Participants must be willing to comply with the requirements of the protocol and have consent to participate in the project.
* Participants must be negative in the urine drug screening visit.

Exclusion Criteria

* Participants with clinical evidence of systemic infection.
* Participants have a history of bone marrow transplantation.
* Participants must have evidence of autoimmune disease, including insulin-dependent diabetes.
* Participant has evidence of significant wound healing prior to treatment (ie, wound closure ≥ 20% during treatment at the first observation period).
* Participant has a severe medical condition, such as malignancy (including skin cancer), life expectancy less than 2 years, which limits movement to the clinical center.
* Participants have a current history of alcohol or substance abuse or a history of alcohol or substance abuse that requires treatment in the past 12 months.
* People participating in the screening should have a positive hepatitis and human immunodeficiency virus (HIV) test result.
* Women who are pregnant, lactating or planning to become pregnant during the study
* Women who are of reproductive age and use birth control pills.

Minimum Eligible Age

3 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No